The surgical robotics market reached $13.8 billion in 2025 and is projected to grow at 16.5% annually through the end of the decade. AI-assisted surgical robotics — systems that combine robotic precision with real-time AI guidance — represent the fastest-growing segment, valued at $7.4 billion in 2025 and projected to reach $96.9 billion by 2032 at a 44.3% compound annual growth rate.
Behind those numbers is a more specific story: robotic surgery has moved from a premium option in a handful of specialties to a standard-of-care option across general surgery, orthopaedics, urology, gynaecology, and increasingly cardiothoracic procedures. The technology is maturing, the clinical evidence is accumulating, and the platform competition has intensified significantly in the past two years.
For engineering teams building in this space — whether clinical software that integrates with robotic platforms, AI systems that assist with surgical guidance, or rehabilitation robotics for post-operative recovery — understanding the current technology landscape and regulatory environment is prerequisite to building anything that reaches clinical use.
The Platform Landscape in 2026
Intuitive Surgical’s da Vinci system dominated surgical robotics for two decades. That dominance is eroding. The FDA cleared four significant new platforms in 2024–2025, each with distinct positioning:
| Platform | Manufacturer | FDA clearance | Key differentiator |
|---|---|---|---|
| da Vinci 5 | Intuitive Surgical | March 2024 | Force feedback (first in surgical robotics); enhanced haptics |
| Versius | CMR Surgical | October 2024 | Modular design; lower capital cost; portable between ORs |
| Maestro | Moon Surgical | 2025 | Collaborative robotics; co-pilot model with surgeon |
| Hugo RAS | Medtronic | EU/US cleared | Open console; compatible with standard laparoscopic instruments |
Stryker’s Mako system — focused on orthopaedic procedures (knee and hip replacement) — reached 600,000 cumulative cases by 2024 and grew 22% in procedure volume in 2025. Mako is the leading example of a specialty-focused robotic system that has achieved genuine market penetration, with strong evidence that robotic-assisted joint replacement produces more consistent implant positioning than manual technique.
Clinical Evidence: What the Data Shows
The clinical evidence for surgical robotics is strongest in procedures where precision and reduced incision size produce measurable patient benefit.
Digestive surgery: A 2025 meta-analysis found robotic GI surgery produced first flatus at 35.1 hours versus 40.7 hours for laparoscopic — a proxy for faster recovery of bowel function. Robotic pancreaticoduodenectomy showed a 3-day shorter hospital stay compared to laparoscopic approach.
AI-assisted surgery specifically: Studies of AI guidance layers added to robotic systems show 25% reductions in operative time and 30% decreases in intraoperative complication rates. The mechanism is consistent: AI systems that provide real-time tissue identification, safe margin delineation, and instrument guidance reduce the cognitive load on the surgeon during complex anatomical dissection.
Emergency surgery: A 2025 retrospective study of emergency general surgery found no significant difference in major complication rates between robotic (10.5%) and laparoscopic (9.1%) approaches — indicating robotic surgery is viable even in time-pressured emergency contexts, not just planned procedures.
Orthopaedics: The Mako system evidence base is extensive. Robotic-assisted knee replacement produces more consistent femoral and tibial component alignment than manual technique in most comparative studies, with some evidence of improved patient-reported outcomes at 2-year follow-up.
AI Integration in Surgical Robotics: Four Patterns
The AI layer in surgical robotics is not a single capability — it is a cluster of distinct functions with different technical approaches.
1. Real-Time Tissue and Anatomy Recognition
Computer vision models trained on surgical video identify anatomical structures in real time — distinguishing the ureter from surrounding tissue in a laparoscopic nephrectomy, or identifying the bile duct during a cholecystectomy to prevent inadvertent injury. This is the highest-stakes AI application in surgical robotics: a false negative (failure to identify a critical structure) can cause a serious intraoperative injury.
The technical requirements: models trained on large, annotated surgical video datasets; real-time inference at the frame rate of the surgical camera (typically 30–60fps) with sub-50ms latency; and uncertainty estimation that surfaces low-confidence predictions for surgeon review rather than displaying incorrect identifications with false confidence.
2. Preoperative Planning and Intraoperative Registration
AI models that generate a 3D surgical plan from preoperative imaging (CT, MRI) and register that plan to the patient’s actual anatomy in the operating room. The Mako system uses this approach for orthopaedic procedures: the surgeon defines the implant position in a preoperative CT-derived 3D model, and the system enforces that plan intraoperatively by constraining the cutting tool to the planned resection boundaries.
The engineering challenge is registration accuracy — the accuracy with which preoperative imaging is aligned to the patient’s intraoperative position. A registration error of 2mm can translate to a clinically significant implant malpositioning. Fiducial markers, intraoperative CT, and optical tracking systems all contribute to maintaining registration accuracy throughout the procedure.
3. Surgeon Skill Assessment and Training
AI systems that analyse surgical video to assess technical performance — instrument handling, economy of motion, tissue handling quality — provide objective metrics for surgical training and credentialling. Unlike subjective faculty assessment, video-based AI scoring is consistent and scalable.
This application is lower regulatory risk than intraoperative AI (it does not influence the procedure in real time) and is increasingly being integrated into surgical residency programmes and robot-assisted procedure credentialling workflows.
4. Post-Procedure Analytics and Outcome Prediction
Aggregating surgical video, patient data, and outcome data to identify performance predictors and outcome risk factors. Which intraoperative events — bleeding episodes, instrument handling patterns, procedure duration — are predictive of 30-day complications? This analytics application requires large multi-site datasets and robust data sharing agreements, but it is increasingly being built into surgical platform data ecosystems.
Rehabilitation Robotics: The Adjacent Market
Surgical robotics captures the most attention, but rehabilitation robotics — devices that assist stroke, spinal cord injury, and orthopaedic patients with motor recovery — is growing rapidly and has a different engineering profile.
The rehabilitation robotics market reached $1.5 billion in 2025 and is growing at 17.5% annually. The key systems:
- Exoskeletons (Ekso Bionics, ReWalk, Indego) — wearable devices that support and augment lower-limb movement for patients with limited motor function. FDA-cleared for clinical use in rehabilitation settings.
- End-effector systems (Hocoma Lokomat, Tyromotion) — devices that move a patient’s limb through repetitive therapeutic motions. Widely used for upper and lower limb rehabilitation.
- Soft robotics — compliant actuator systems that can assist movement without the rigidity of traditional robotic arms. Emerging for hand and wrist rehabilitation.
The AI integration in rehabilitation robotics focuses on adaptive control — adjusting the level of robotic assistance in real time based on the patient’s effort level, preventing learned helplessness (over-assistance reduces neuroplasticity-driven recovery) while providing enough support for safe repetitive practice.
Regulatory Requirements for Healthcare Robotics Software
Software integrated with surgical or rehabilitation robotic systems is regulated as Software as a Medical Device (SaMD) under FDA oversight. The specific classification depends on the intended use and the risk level of the software’s output.
Class II (510(k)): Most surgical guidance and decision support software falls in this category. Requires demonstrating substantial equivalence to a predicate device. Timeline: 12–18 months typical from submission.
Class III (PMA): Novel technologies with no predicate, or technologies intended for life-sustaining functions. Requires clinical trial data demonstrating safety and effectiveness. Timeline: 3–7 years.
The practical implications for engineering teams:
- Document the intended use precisely — “assists surgeons in identifying tissue boundaries” is materially different from “autonomously controls instrument movement.” The former may be Class II; the latter is likely Class III.
- Build design controls from day one — design history file, risk management (ISO 14971), and software development lifecycle documentation are required for FDA submission and are far more expensive to reconstruct after the fact than to maintain during development.
- FHIR integration matters here too — surgical platforms that connect to EHR systems to pull preoperative patient data need to handle PHI correctly, with BAAs in place for all data processors.
How we approach this at Insoftex
The real-time data processing, safety-critical AI design, and audit logging architecture that healthcare robotics requires are patterns we have built in adjacent regulated contexts. Our AI-powered healthcare platform was designed with HIPAA compliance and FHIR integration as first-class constraints from the start — the same compliance posture that surgical robotics platforms require when connecting to EHR systems for preoperative patient data. The BAA architecture review covering all PHI-touching vendors, including the FHIR integration layer and any analytics services that capture request payloads, is a standard deliverable in our healthcare scoping engagements.
The real-time telemetry and control architecture from our industrial IoT monitoring work shares structural characteristics with the sensor data pipelines that rehabilitation robotics and surgical systems require — specifically, the edge-to-cloud pattern for high-frequency, latency-sensitive data, and the anomaly detection layer that must operate with predictable latency regardless of cloud connectivity. The design principle in safety-critical contexts: the primary control loop must not share infrastructure with the analytics and reporting stack. Dashboard queries that degrade control response times under load are an architectural failure mode, not a performance tuning problem.
The FDA SaMD classification and design controls requirement is where we begin scoping on any healthcare robotics software engagement. The intended use statement — specifically whether the software assists with information or exercises autonomous control — determines the regulatory pathway and the timeline before clinical deployment. We run this classification assessment in the Product Pilot, alongside the HIPAA architecture review, because the classification result can eliminate model architecture options and changes the build timeline significantly. Discovering you need a PMA rather than a 510(k) mid-build is a programme-level finding, not a technical one.
Building software for a surgical robotics or rehabilitation robotics platform? Our Product Pilot covers FDA SaMD classification, architecture design, and HIPAA integration in three weeks.
Frequently Asked Questions
What FDA clearance is required for AI software used in surgical robotics?
AI software integrated with surgical robotic systems is regulated as Software as a Medical Device (SaMD). The clearance pathway depends on the software's intended use and risk level. Software that assists surgeons with information (tissue identification, boundary delineation, preoperative planning visualisation) without autonomous control of instruments is typically Class II and can seek 510(k) clearance by demonstrating substantial equivalence to a predicate device — typical timeline 12–18 months from submission. Software that autonomously controls instrument movement or makes clinical decisions without surgeon review is likely Class III and requires a Premarket Approval (PMA) application with clinical trial evidence — typical timeline 3–7 years. The boundary between Class II and Class III depends on the specifics of the intended use statement, the degree of autonomous action, and the consequences of software error. FDA's Digital Health Center of Excellence provides pre-submission meetings that can clarify the pathway before significant development investment is made.
How is the da Vinci 5 different from the previous da Vinci systems?
The da Vinci 5 (FDA cleared March 2024) introduced force feedback — haptic sensing that allows the surgeon to feel resistance when instruments contact tissue. This is the first force feedback capability in a commercially cleared surgical robotic system. Previous da Vinci systems provided visual feedback only; surgeons compensated for the absence of tactile feedback through experience and visual cues, but force feedback is clinically significant for delicate tissue handling. The da Vinci 5 also improved instrument wrist articulation, upgraded the imaging system with 4K resolution, and added real-time performance metrics for each procedure. Intuitive positioned it as both a clinical upgrade and a data platform — the system generates structured procedure data that feeds into Intuitive's case analytics offerings.
What is the difference between surgical robotics and collaborative robotics in healthcare?
Traditional surgical robotic systems (da Vinci, Mako) place the surgeon at a remote console, translating their movements into scaled, filtered instrument motion at the operative field. The robot executes what the surgeon inputs; the surgeon is physically separated from the patient and instruments. Collaborative robotics (the Maestro system from Moon Surgical is the clearest example in surgery) places the robot alongside the surgeon at the table, augmenting the surgeon's direct hand movements rather than replacing them. The surgeon holds and guides instruments; the robot provides stabilisation, tremor filtering, and constraint enforcement. Collaborative systems require less surgeon retraining (the hand-eye coordination is similar to open surgery), have a lower capital cost, and are easier to integrate into existing OR workflow. The trade-off is less amplification of precision — the robot enhances but does not substitute for the surgeon's manual skill.
What data infrastructure does a surgical robotics platform need for AI development?
Surgical AI development requires three data infrastructure components. First, surgical video storage and annotation: high-definition surgical video (typically 4K at 30–60fps) generates large files; a pipeline for storing, de-identifying, annotating, and versioning this video is the foundation for all computer vision model development. DICOM-SR and structured reporting standards are increasingly used to attach annotations to video. Second, a multi-site data sharing framework: single-institution surgical datasets are rarely large enough to train robust AI models. Multi-site data sharing requires standardised data formats, de-identification protocols, data use agreements (DUAs) between institutions, and a federated or centralised data lake architecture. Third, a model evaluation infrastructure: surgical AI models must be evaluated on prospective cases from institutions not represented in training data before clinical deployment. Build the evaluation pipeline — annotation tooling, metric definition, statistical testing framework — before the model, not after.